Publications by authors named "Ana C Puga"

Claim this Profile
H
How a concentration-effect analysis of data from the eliglustat thorough electrocardiographic study was used to support dosing recommendations.
Jeremy N Ruskin, Catherine Ortemann-Renon, Jerome Msihid, Leorah Ross, Ana Cristina Puga

Mol Genet Metab· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents.
Nathan Thibault, Jennifer Ibrahim, M Judith Peterschmitt, Ana Cristina Puga, Leorah Ross

Mol Genet Metab· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months.
Melissa P Wasserstein, George A Diaz, Robin H Lachmann, Marie-Hélène Jouvin, Indrani Nandy, Ana Cristina Puga

J Inherit Metab Dis· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Systems Pharmacology Modeling of Acid Sphingomyelinase Deficiency and the Enzyme Replacement Therapy Olipudase Alfa Is an Innovative Tool for Linking Pathophysiology and Pharmacology.
Chanchala D Kaddi, Bradley Niesner, Rena Baek, Paul Jasper, John Pappas, Ana Cristina Puga

CPT Pharmacometrics Syst Pharmacol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase Deficiency.
Beth L Thurberg, Melissa P Wasserstein, Simon A Jones, Thomas D Schiano, Gerald F Cox, Ana Cristina Puga

Am J Surg Pathol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.
Melissa P Wasserstein, Simon A Jones, Handrean Soran, George A Diaz, Natalie Lippa, Ana Cristina Puga

Mol Genet Metab· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
Timothy M Cox, Guillermo Drelichman, Renata Cravo, Manisha Balwani, Thomas Andrew Burrow, Ana Cristina Puga

Lancet· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.
Elena Lukina, Nora Watman, Marta Dragosky, Gregory M Pastores, Elsa Avila Arreguin, Ana Cristina Puga

Blood Cells Mol Dis· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat.
Ravi S Kamath, Elena Lukina, Nora Watman, Marta Dragosky, Gregory M Pastores, Ana Cristina Puga

Skeletal Radiol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers.
M Judith Peterschmitt, Amy Burke, Larry Blankstein, Sharon E Smith, Ana Cristina Puga

J Clin Pharmacol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome.
Joseph Muenzer, Michael Beck, Christine M Eng, Roberto Giugliani, Paul Harmatz, Ana Cristina Puga

Genet Med· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study.
Elena Lukina, Nora Watman, Elsa Avila Arreguin, Marta Dragosky, Marcelo Iastrebner, Ana Cristina Puga

Blood· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.
Elena Lukina, Nora Watman, Elsa Avila Arreguin, Maryam Banikazemi, Marta Dragosky, Ana Cristina Puga

Blood· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective study of 11 Brazilian patients with mucopolysaccharidosis II.
Louise L C Pinto, Ida V D Schwartz, Ana C S Puga, Taiane A Vieira, Maria Verônica R Munoz

J Pediatr (Rio J)· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of a pioneer metabolic information service in Brazil.
Silvia Brustolin, Carolina Souza, Ana Cristina Puga, Lilia Refosco, Ricardo Pires

Community Genet· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome).
Joseph Muenzer, James E Wraith, Michael Beck, Roberto Giugliani, Paul Harmatz, Ana Cristina Puga

Genet Med· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arginase deficiency with lethal neonatal expression: evidence for the glutamine hypothesis of cerebral edema.
Jonathan D Picker, Ana C Puga, Harvey L Levy, Deborah Marsden, Vivian E Shih

J Pediatr· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis